Iovance Biotherapeutics, Inc. Common Stock Profile
About
Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
Info & Links
CEO
Frederick G. Vogt
Headquarters
825 INDUSTRIAL ROAD, SUITE 400 SAN CARLOS, CA 94070, UNITED STATES
Iovance Biotherapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
1.07B
Enterprise Value
959.10M
Enterprise Value/EBITDA(ttm)
-2.65
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
18.82
Price to Book(mrq)
2.03
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
-211.54%
Operating Margin(ttm)
-451.25%
Profit Margin(ttm)
-4090.57%
Return on Equity(ttm)
-58.43%
Return on Invested Capital(ttm)
-51.04%
Return on Assets(ttm)
-45.48%
Income Statement
Revenue(ttm)
164.07M
Revenue Per Share(ttm)
0.50
Gross Profit(ttm)
40.07M
EBITDA(ttm)3
-361.93M
Net Income Available to Common(ttm)
-372.18M
Diluted EPS(ttm)
-1.49
Share Statistics
Beta (5Y Monthly)
0.53
52-Week Change
-72.39%
S&P 500 52-Week Change
7.92%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
327.88M
Dividend Yield
0.00%
Float4
267.90M
% Held by Insiders
12.10%
% Held by Institutions
77.03%
Balance Sheet
Total Cash(mrq)
323.78M
Total Cash Per Share(mrq)
0.99
Total Debt(mrq)
1000.00K
Total Debt/Equity(mrq)
0.14%
Current Ratio(mrq)
3.74%
Quick Ratio(mrq)
3.90%
Book Value Per Share(mrq)
2.33
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.22
Free Cash Flow(ytd)
-364.05M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.